Use of Medication for Cardiovascular Disease During Pregnancy: JACC State-of-the-Art Review.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 30704579.
- Also identified by DOI 10.1016/j.jacc.2018.10.075.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cardiovascular disease complicating pregnancy is rising in prevalence secondary to advanced maternal age, cardiovascular risk factors, and the successful management of congenital heart disease conditions. The physiological changes of pregnancy may alter drug properties affecting both mother and fetus. Familiarity with both physiological and pharmacological attributes is key for the successful management of pregnant women with cardiac disease. This review summarizes the published data, available guidelines, and recommendations for use of cardiovascular medications during pregnancy. Care of the pregnant woman with cardiovascular disease requires a multidisciplinary team approach with members from cardiology, maternal fetal medicine, anesthesia, and nursing.
Medical subject headings
- Cardiovascular Agents
- Pregnancy Complications, Cardiovascular